PMID- 35973639
OWN - NLM
STAT- MEDLINE
DCOM- 20220913
LR  - 20221111
IS  - 1521-7035 (Electronic)
IS  - 1521-6616 (Linking)
VI  - 242
DP  - 2022 Sep
TI  - Will fecal microbiota transplantation eventually be an effective therapeutic 
      strategy for systemic lupus erythematosus?
PG  - 109096
LID - S1521-6616(22)00177-2 [pii]
LID - 10.1016/j.clim.2022.109096 [doi]
AB  - Gut microbiota dysbiosis serves as a potential trigger that may contribute to 
      metabolic and immune dysregulation that underlies the development of autoimmune 
      diseases. Fecal microbiota transplantation (FMT) is restoration of disturbed 
      microbiota by transplanting foreign gut microbiota from healthy individuals into 
      the gastrointestinal tract of diseased individuals. In this issue of the Journal 
      of Autoimmunity, Huang et al. conducted a 12-week, single-arm pilot clinical 
      trial of oral FMT capsules in patients with active SLE. No serious adverse events 
      (AEs) or deaths were observed and the rate of the primary endpoint (SLE Responder 
      Index-4) was 42.12%. Alternations in bacteria, metabolites and immune parameters 
      were linked to FMT treatment and clinical response in SLE patients. This is the 
      first FMT trial in SLE patients and provides supportive evidence that FMT appears 
      to be a safe, feasible and potentially effective treatment modality in SLE. We 
      await future investigations conducting larger, randomized FMT clinical trials 
      with a longer follow-up to confirm the long-term safety, effectiveness, and 
      potential benefits of FMT-based intervention in SLE and to further demonstrate 
      the underlying microbiological mechanisms.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Ciccia, Francesco
AU  - Ciccia F
AD  - Department of Precision Medicine, University della Campania L. Vanvitelli, 
      Naples, Italy. Electronic address: francesco.ciccia@unicampania.it.
FAU - Gandolfo, Saviana
AU  - Gandolfo S
AD  - Rheumatology Unit, Azienda Ospedaliera San Giovanni Bosco, Naples, Italy.
LA  - eng
PT  - Journal Article
DEP - 20220813
PL  - United States
TA  - Clin Immunol
JT  - Clinical immunology (Orlando, Fla.)
JID - 100883537
SB  - IM
MH  - Dysbiosis/therapy
MH  - Fecal Microbiota Transplantation/adverse effects
MH  - Feces/microbiology
MH  - Humans
MH  - *Lupus Erythematosus, Systemic/etiology/therapy
MH  - *Microbiota
MH  - Treatment Outcome
EDAT- 2022/08/17 06:00
MHDA- 2022/09/14 06:00
CRDT- 2022/08/16 19:34
PHST- 2022/07/20 00:00 [received]
PHST- 2022/08/02 00:00 [revised]
PHST- 2022/08/04 00:00 [accepted]
PHST- 2022/08/17 06:00 [pubmed]
PHST- 2022/09/14 06:00 [medline]
PHST- 2022/08/16 19:34 [entrez]
AID - S1521-6616(22)00177-2 [pii]
AID - 10.1016/j.clim.2022.109096 [doi]
PST - ppublish
SO  - Clin Immunol. 2022 Sep;242:109096. doi: 10.1016/j.clim.2022.109096. Epub 2022 Aug 
      13.